Genomic Prediction

Open enrollment across a mixed-phase pipeline

According to ClinicalTrials.gov-derived indexes, Genomic Prediction sits in the upper quartile of US sponsors by registered trial count (#2,085 of 15,742 sponsors by registered trial count).

6 total trials 4 currently recruiting upper quartile by trial count

Genomic Prediction: 6 sponsored US clinical trials, 4 recruiting.

Genomic Prediction sponsors 6 registered US clinical trials on ClinicalTrials.gov, 4 of them currently recruiting. The most-studied condition in this pipeline is Infertility, with 3 trials.

Upper-quartile sponsor footprint

Genomic Prediction sits in the upper quartile of the sponsor corpus (#2,085 of 15,742 sponsors by registered trial count) - denser than most sponsors, still short of the top-decile hubs.

What is open in the Genomic Prediction pipeline

4 recruiting of 6 indexed (67% open).

Phase labels are sparse on this sponsor index, so phase mix is not charted here.

Top condition: Infertility (3 trials), 6 others listed.

How open-pipeline share is computed

Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.

Genomic Prediction: open-pipeline peers nationwide

Peers matched on 6 registered trials and 67% open enrollment, not the therapeutic-area sidebar.

Genomic Prediction sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 234567 0%20%40%60%80% Total trials Recruiting share Genomic Prediction23andMeAardvark TherapeuticsAbbisko Therapeutics CoAbGenomics B.V Taiwan BranchABL BioAccelerated Cure Project for Multiple SclerosisAdvanced Reconstructive Surgery AllianceAlexander B Olawaiye, MD
Genomic Prediction sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

Genomic Prediction sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 6 trials (± recruiting share)

Sponsors near 67% open enrollment (± trial volume)

What to do with this Genomic Prediction page

6 registered trials is a research-attention snapshot, not an endorsement of Genomic Prediction or any single study.

  • 4 of Genomic Prediction's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
  • Infertility is the condition Genomic Prediction studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Infertility trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Genomic Prediction pipeline card: 6 registered trials from official public datasets.Report a data error.